Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
This was a multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of canakinumab plus standard-of-care (SOC) compared with placebo plus SOC in patients with COVID-19-induced pneumonia and cytokine release syndrome (CRS).
Epistemonikos ID: 0217df847c709cef22197eacc761973a925d1b8a
First added on: Apr 28, 2020